Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Hester J. Scheffer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6298-383X; OpenAlex author ID A5024500835. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2017: 4 papers · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 20

  1. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE t… Co-author DOI 10.1136/jitc-2024-010222↗
  2. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE… Co-author DOI 10.1016/s2468-1253(24)00017-7↗
  3. Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply. Co-author DOI 10.1016/s2468-1253(24)00162-6↗
  4. Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival. Co-author DOI 10.1016/j.jvir.2023.06.027↗
  5. Transcatheter CT arteriography-guided irreversible electroporation of locally advanced pancreatic adenocarcinoma: A pictorial essay. Co-author DOI 10.1111/1754-9485.13535↗
  6. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. Co-author DOI 10.1007/s11912-021-01057-3↗
  7. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Last author DOI 10.3390/cancers13071608↗
  8. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Meta… Co-author DOI 10.3390/cancers13153902↗
  9. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Co-author DOI 10.3390/cancers13164138↗
  10. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. Co-author DOI 10.1016/j.jvir.2020.02.024↗
  11. Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Last author DOI 10.1016/j.tvir.2020.100675↗
  12. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Co-author DOI 10.1148/radiol.2019191109↗
  13. Exocrine pancreatic and enterocyte function in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.clnu.2018.12.005↗
  14. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activati… Co-author DOI 10.1080/2162402x.2019.1652532↗
  15. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? Co-author DOI 10.21037/cco.2019.10.05↗
  16. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Co-author DOI 10.3390/cancers10010016↗
  17. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. First author DOI 10.1007/s00330-016-4581-2↗
  18. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jvir.2016.10.023↗
  19. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Co-author DOI 10.1148/radiol.2016152835↗
  20. Assessment of Nutritional Status, Digestion and Absorption, and Quality of Life in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1155/2017/6193765↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martijn Ruben Meijerink · 19 shared papers, 2017–2025 · strength 2.37
  2. Bart Geboers · 13 shared papers, 2019–2025 · strength 1.87
  3. Florentine E. F. Timmer · 10 shared papers, 2020–2025 · strength 1.57
  4. Alette H. Ruarus · 10 shared papers, 2018–2025 · strength 1.23
  5. Tanja D. de Gruijl · 10 shared papers, 2017–2025 · strength 1.21
  6. Laurien G. P. H. Vroomen · 9 shared papers, 2017–2025 · strength 0.99
  7. Anna M E Bruynzeel · 4 shared papers, 2021–2025 · strength 0.76
  8. Geert Kazemier M · 6 shared papers, 2017–2020 · strength 0.48
  9. Frank J. Lagerwaard · 2 shared papers, 2024–2025 · strength 0.37
  10. Johanna W. Wilmink · 3 shared papers, 2020–2021 · strength 0.31
  11. Marc G. Besselink · 3 shared papers, 2017–2020 · strength 0.25
  12. Marian A.E. de van der Schueren · 3 shared papers, 2017–2019 · strength 0.24
  13. Jill E. Witvliet-van Nierop · 3 shared papers, 2017–2019 · strength 0.24
  14. Krijn P. van Lienden · 2 shared papers, 2020 · strength 0.19
  15. Eran van Veldhuisen · 2 shared papers, 2020 · strength 0.19
  16. Nicolette Wierdsma · 2 shared papers, 2017–2019 · strength 0.18
  17. Babs M. Zonderhuis · 2 shared papers, 2017–2020 · strength 0.15
  18. Jantien A. Vogel · 2 shared papers, 2017–2020 · strength 0.15
  19. Jose M. Yrizarry · 1 shared paper, 2017 · strength 0.06
  20. Govindarajan Narayanan · 1 shared paper, 2017 · strength 0.06
  21. Caio Rocha‐Lima · 1 shared paper, 2017 · strength 0.06
  22. Riccardo Antonio Lencioni · 1 shared paper, 2017 · strength 0.06
  23. Peter J. Hosein · 1 shared paper, 2017 · strength 0.06
  24. Jaime Rafael Merchan · 1 shared paper, 2017 · strength 0.06
  25. Freek D. Daams · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.